SYT17

Across TCGA pan-cancer cohorts, SYT17 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SYT17 data layer compared with 19 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher SYT17 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SYT17 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, SKCM, and CESC are the cancer types where SYT17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
SKCM	OS	Median	IV	0.179	0.755	<.001	9	view →
CESC	OS	Median	II,III,IV	0.227	0.759	.029	6	view →
UCEC	DFS	Median	All	0.967	0.830	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SYT17–ACC (DFS)

Open the ACC breakdown →